It might make ya grow man #$%$ and mess up the male hormonal system.
I actually have an AI disease...not MS -- but I wish it did. There is a huge need for treatment for men. Some say Testosterone...but I'm not sure it has been proven.
I do know some secrets for men if anyone happens to have MS.
Women are in luck though, because this combined with Copaxone will help a lot.
Second largest holding right now is JVA -- coffee beans Will hold for at least $10.00.
Largest holding: SYN - I love the future of that one... Major Catalyst April 29th.
I got out of RNN because AF bashed the heck out of it and it is just a manipulated stock.
CTIX right now rates 6th -- but that could change sooner or later.
is something else. They trash the stock one day and the next they replay parts of the positive interview.
Will there EVER be anyone HONEST in the Stock Reporting business?
CN BS is does nothing but report what they are Paid to Report by Hedgies.
I hear ya Nick.
I have been through that also. I owned JAZZ at $2 a share. Sold for under $4 I believe it was. Now it is almost $200. STUPID on my part, but these are so difficult to predict, but if results are good, this one could be the next $200 one I was in on below $10 and this time I will hold and reap the rewards.
Everyone is giving a thumbs up but it is Common Sense that Deerfield does this prior to Adcom and Pdufa date.
I'm Sorry Ep
I will try to give you an answer if you are referring to the Roth conference.
Actually the focus was on the Future Beyond Trimesta. I believe the results will be good.
Jeff was very loose as you could tell from his voice and just from that perception I'm more confident than ever. Look, this stock as EVERY stock can be manipulated.
I would say buy the dips, every dip.
Jeff focused was more on the Multi-Billion Dollar pipeline and it was like he said really wanted to stamp that point that it is not ALL about Trimesta as they have so much potential.
Sorry, I haven't been reading many posts, just been posting.
If that didn't answer your Q, just type a new post with Gizmo Question.
I am going back and forth trading others right now....get back as soon as I can.
This is another Ariad...EXACT same thing here.
The FDA will allow this for blood cancers and the stock will skyrocket in about two months.
But it may be shaky for a while.
That Freaking BgLightweight was in the KNOW on this one just when RNN got shorted down.
That dude should be investigated.
I guess the next time I see him I won't take him so lightly...twice burned by that guy.
The C. Diff program is great for long term. The Binary event is MS, but that is just the first piece of the pie. They have programs that can really change medine.
60-65% of the company is very closely held. 35% is floating.
A lot of institutions are buying at the market. I don’t think we are a company to short as we have a ton of good data coming out.
That is it, ending with clapping.
Pretty Cool Huh!
The constipation type of drug is 40% of the IBS market which is huge.
Ironwood and Forest are controlling this market right now, but it is not very well treated with their laxatives.
Methane Gas slows the digestive process. This is a Multi Billion Dollar opportunity.
C. Diff Drug: Most are acquired in the hospital with the use of Antibiotics because it wipes out of positive microbiome. This is a highly contagious disease with 30,000 people a year dying. The current treatment is treating with Stronger Antibiotics which doesn’t make sense. SYN approach is to swallow a pill which goes straight the Large Bowel and does its job. The drug breaks the antibiotics down. They know that this drug works. So now they will get into a Phase I-b this year. In 2015 the hospitals have to absorbed these costs…so they believe that EVERY hospital will use this to save big $$$ for the hospitials. The pill will cost $25 and they are working with the CDC on this program. Multi-Billion opp here.
Whooping Cough Drug: Baby Baboon results coming soon. The toxins from this stay in the tracheal area for a long time. SYN has a drug that binds with this toxin and detoxifies it so the body can eliminate it.
We don’t know if these are going to work yet.
IBS – trying to eliminate ALL of IBS…this is just beginning stage.
Burn Rate: $1 Million a month.
Volume has increased significantly.
$15 million market cap increased 10 fold to $150 million.
A plethora of data expected this year.
Multiple Sclerosis Topline
Phase II or even III after talks with FDA on IBS at least a phase II is
Sept to Oct: More MS Data….the Deep Data
C. Diff – IND filing, the manufacturing and then Phase I-a to Phase I-b.
As investors looking at your company…how do you think investors view the priority driver of shareprice?
Jeff: It is a combination. The MS is the real driver. The rest of the programs are “real sexy”.
Part I:Roth Presentation of Synthetic Biologics 3-11-2014:
It begins by “this company has the backing of a very successful health care investor by the name of R.J Kirk.”
Jeff Riley: CEO of SYN. Market Cap around $150 Million give or take. We have a variety of products in the clinic. Jeff runs a hedgefund and they are an RJ Kirk company. They have an outstanding team.
We have a pretty good feeling about upcoming results.
C. Diff, Whooping Cough
Programs with Intrexon
Estriol – hormone produced by placenta in third trimester of pregnancy. 20-25 years ago they discovered the inflammatory properties of this. It lasts 3 months. Phase I was so successful that they have $8 million of donations that funded the entire program and have not spent a dime of their own money.
January 24th, was the last patient.
Copaxone combined with Estriol.
Market is $14 Billion Dollars. It is an undertreated market.
SYN management decided to choose Anti-Infective drugs specifically to focus on. They go after a Sniper Approach to a pathogen specific biologic approach.
The microbiome has come to the forfront of medicine…90% of our bodies are made up of Bacteria....most have positive roles. Antibiotics have wiped our Microbiome out.
2 Years ago this space was not very good, but the GAIN act signed in 2011 was the Orphan Drug act for new Antibiotic Discoveries. Now there are a variety of deals accomplished for newer antibiotics. Cubist the leader is making acquisitions right now.
1 in 4 chance of having a successful drug if it works in the petree dish.
Acquired from Cedar Sinai….SYN is targeting bugs in the small intestine and large intestine…these bugs cause bloating and constipation. SYN010….they measure methane gas in the breath and the drug is administered for once a day until symptoms reside. The markets are quite large and underserved. So they have two markets: one of diagnosis and one of treatment.